

Ottavio Chnio De Cobelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2729921/publications.pdf>

Version: 2024-02-01

269
papers

6,416
citations

61984

43
h-index

114465

63
g-index

277
all docs

277
docs citations

277
times ranked

7164
citing authors

#	ARTICLE	IF	CITATIONS
1	External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection. World Journal of Urology, 2023, 41, 619-625.	2.2	8
2	Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy. European Urology Focus, 2022, 8, 457-464.	3.1	14
3	Ultrahypofractionated radiotherapy for localized prostate cancer with simultaneous boost to the dominant intraprostatic lesion: a plan comparison. Tumori, 2022, 108, 263-269.	1.1	4
4	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. Urologia Internationalis, 2022, 106, 75-82.	1.3	4
5	Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 11.e9-11.e15.	1.6	9
6	Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses. European Journal of Surgical Oncology, 2022, 48, 687-693.	1.0	12
7	Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair Analysis (ROBUUST Collaborative Group). Journal of Endourology, 2022, 36, 752-759.	2.1	22
8	Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer. Cancer Management and Research, 2022, Volume 14, 89-101.	1.9	2
9	Comparison Between Micro-Ultrasound and Multiparametric MRI Regarding the Correct Identification of Prostate Cancer Lesions. Clinical Genitourinary Cancer, 2022, 20, e339-e345.	1.9	6
10	Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis. Neoplasma, 2022, , .	1.6	0
11	A comprehensive evaluation of sexual and reproductive outcomes following robot-assisted retroperitoneal lymph node dissection for nonseminomatous germ cell tumor. Asian Journal of Andrology, 2022, 24, 579.	1.6	6
12	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 273.e11-273.e20.	1.6	8
13	The Clinical Role of SRSF1 Expression in Cancer: A Review of the Current Literature. Applied Sciences (Switzerland), 2022, 12, 2268.	2.5	4
14	Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy. Diagnostics, 2022, 12, 586.	2.6	14
15	Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology Young Academic Urologists. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 195.e27-195.e35.	1.6	5
16	Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International Consortium. Minerva Urology and Nephrology, 2022, 74, 186-193.	2.5	9
17	Progress in prostate cancer prevention. European Journal of Cancer Prevention, 2022, 31, 554-557.	1.3	5
18	Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World Journal of Urology, 2022, 40, 1505-1512.	2.2	12

#	ARTICLE	IF	CITATIONS
19	Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e166-e172.	1.9	26
20	Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The Tj ETQq0 0 0 rgBT Lock 10 Tf 50 69		
21	Radiomics in prostate cancer: an up-to-date review. <i>Therapeutic Advances in Urology</i> , 2022, 14, 175628722211090.	2.0	62
22	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. <i>World Journal of Urology</i> , 2021, 39, 443-451.	2.2	13
23	How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. <i>World Journal of Urology</i> , 2021, 39, 1445-1452.	2.2	0
24	MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 406-413.	3.9	9
25	Adjuvant radiotherapy in node positive prostate cancer patients: a debate still on. when, for whom?. <i>BJU International</i> , 2021, 127, 454-462.	2.5	3
26	Increased Mortality Among Men Diagnosed With Impaired Fertility: Analysis of US Claims Data. <i>Urology</i> , 2021, 147, 143-149.	1.0	22
27	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103198.	4.4	35
28	Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer. <i>Surgical Oncology</i> , 2021, 36, 131-137.	1.6	4
29	Robot-Assisted Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of Urinary Bladder: A Comparison Between Intracorporeal Versus Extracorporeal Orthotopic Ileal Neobladder. <i>Journal of Endourology</i> , 2021, 35, 151-158.	2.1	13
30	MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218). <i>European Radiology</i> , 2021, 31, 716-728.	4.5	31
31	Impact of uni- or multifocal perineural invasion in prostate cancer at radical prostatectomy. <i>Translational Andrology and Urology</i> , 2021, 10, 66-76.	1.4	5
32	Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110371.	2.0	5
33	Quality of life and psycho-emotional wellbeing in bladder cancer patients and their caregivers: a comparative analysis between urostomy versus ileal orthotopic neobladder. <i>Ecancermedalscience</i> , 2021, 15, 1163.	1.1	8
34	Impact of Perioperative Immunonutrition on Complications in Patients Undergoing Radical Cystectomy: A Retrospective Analysis. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542110194.	2.0	5
35	Assessment of PSIM (Prostatic Systemic Inflammatory Markers) Score in Predicting Pathologic Features at Robotic Radical Prostatectomy in Patients with Low-Risk Prostate Cancer Who Met the Inclusion Criteria for Active Surveillance. <i>Diagnostics</i> , 2021, 11, 355.	2.6	12
36	Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 237.	2.5	58

#	ARTICLE	IF	CITATIONS
37	Apparent Diffusion Coefficient and Other Preoperative Magnetic Resonance Imaging Features for the Prediction of Positive Surgical Margins in Prostate Cancer Patients Undergoing Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e335-e345.	1.9	7
38	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-â€œclear Cell Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , 2021, 7, 598-607.	3.1	10
39	Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies. <i>European Urology Open Science</i> , 2021, 27, 19-28.	0.4	11
40	BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored. <i>Diagnostics</i> , 2021, 11, 908.	2.6	26
41	Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer. <i>Surgical Oncology</i> , 2021, 37, 101519.	1.6	2
42	Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review. <i>Cancers</i> , 2021, 13, 3278.	3.7	6
43	A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. <i>Future Oncology</i> , 2021, 17, 3987-3994.	2.4	3
44	Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. <i>Future Science OA</i> , 2021, 7, FSO709.	1.9	40
45	Robot-Assisted Intracorporeal Orthotopic Ileal Neobladder: Description of the â€œShellâ€œ-Technique. <i>Journal of Clinical Medicine</i> , 2021, 10, 3601.	2.4	4
46	Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 732766.	2.8	2
47	The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. <i>Minerva Urology and Nephrology</i> , 2021, 73, 442-451.	2.5	23
48	Prostate Cancer Radiogenomicsâ€”From Imaging to Molecular Characterization. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9971.	4.1	55
49	Uro-oncologic patient management during the COVID-19 pandemic: survey findings from an Italian oncologic hub. <i>Future Oncology</i> , 2021, 17, 3615-3625.	2.4	0
50	Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 885-893.	0.4	11
51	Penile-sparing surgery for patients with superficial or initially invasive squamous cell carcinoma of the penis: long-term oncological outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 736.e1-736.e7.	1.6	2
52	Mechanical and Ablative Minimally Invasive Techniques for Male LUTS due to Benign Prostatic Obstruction: A Systematic Review according to BPH-6 Evaluation. <i>Urologia Internationalis</i> , 2021, 105, 858-868.	1.3	9
53	Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 626-635.	1.4	20
54	Prostate-specific Membrane Antigen Positron Emission Tomography, Not Conventional Imaging, Should Be Performed for Primary Staging of High-risk Prostate Cancer. <i>European Urology Open Science</i> , 2021, 34, 17-18.	0.4	2

#	ARTICLE	IF	CITATIONS
55	The role of MRI in the management of a prostate cancer patient with bone and lymph nodes metastases. A case report. <i>Acta Biomedica</i> , 2021, 92, e2021214.	0.3	0
56	Automating Endoscope Motion in Robotic Surgery: A Usability Study on da Vinci-Assisted Ex Vivo Neobladder Reconstruction. <i>Frontiers in Robotics and AI</i> , 2021, 8, 707704.	3.2	11
57	Impact of the Treatment of <i>Serenoa repens</i> , <i>Solanum lycopersicum</i> , Lycopene and Bromelain in Combination with Alfuzosin for Benign Prostatic Hyperplasia. Results from a Match-Paired Comparison Analysis. <i>Uro</i> , 2021, 1, 228-237.	0.8	3
58	Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300. <i>Frontiers in Oncology</i> , 2021, 11, 778729.	2.8	1
59	Finding safe dose-volume constraints for re-irradiation with SBRT of patients with prostate cancer relapse: The IEO experience. <i>Physica Medica</i> , 2021, 92, 62-68.	0.7	4
60	Postoperative vacuum therapy following AMS [®] , LGX 700 [®] inflatable penile prosthesis placement: penile dimension outcomes and overall satisfaction. <i>International Journal of Impotence Research</i> , 2020, 32, 133-139.	1.8	6
61	Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). <i>World Journal of Urology</i> , 2020, 38, 151-158.	2.2	23
62	Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 129-137.e3.	1.9	11
63	Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 94-101.	3.9	4
64	Conditional survival of patients with stage III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. <i>World Journal of Urology</i> , 2020, 38, 725-732.	2.2	10
65	Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis. <i>World Journal of Urology</i> , 2020, 38, 1535-1544.	2.2	8
66	Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e450-e456.	1.9	5
67	Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 117-128.e5.	1.9	6
68	Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs. <i>Medicine (United States)</i> , 2020, 99, e20200101.	10	50
69	Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies. <i>World Journal of Urology</i> , 2020, 39, 1861-1867.	2.2	14
70	Mixed-beam approach for high-risk prostate cancer: Carbon-ion boost followed by photon intensity-modulated radiotherapy. Dosimetric and geometric evaluations (AIRC IG-14300). <i>Physica Medica</i> , 2020, 76, 327-336.	0.7	4
71	Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 929.e11-929.e19.	1.6	8
72	Radical penectomy, a compromise for life: results from the PECAD study. <i>Translational Andrology and Urology</i> , 2020, 9, 1306-1313.	1.4	9

#	ARTICLE	IF	CITATIONS
73	Phase II prospective trial "Give Me Five" short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218). <i>Medical Oncology</i> , 2020, 37, 74.	2.5	7
74	The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 567-574.	1.3	3
75	Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels. <i>Cancer Imaging</i> , 2020, 20, 77.	2.8	11
76	Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center. <i>Scandinavian Journal of Urology</i> , 2020, 54, 382-386.	1.0	2
77	How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency?. <i>Frontiers in Surgery</i> , 2020, 7, 563006.	1.4	17
78	Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma. <i>Metabolites</i> , 2020, 10, 509.	2.9	51
79	Long-Term Follow-Up Outcomes after Percutaneous US/CT-Guided Radiofrequency Ablation for cT1a-b Renal Masses: Experience from Single High-Volume Referral Center. <i>Cancers</i> , 2020, 12, 1183.	3.7	15
80	Robot-assisted inguinal lymphadenectomy: preliminary experience and perioperative outcomes from an Italian referral center. <i>Therapeutic Advances in Urology</i> , 2020, 12, 175628722091338.	2.0	3
81	SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?. <i>Urologia Internationalis</i> , 2020, 104, 510-522.	1.3	17
82	A Guide for Oncologic Patient Management during Covid-19 Pandemic: The Initial Experience of an Italian Oncologic Hub with Exemplificative Focus on Uro-Oncologic Patients. <i>Cancers</i> , 2020, 12, 1513.	3.7	11
83	Minimally invasive versus open radical cystectomy: long term oncologic outcomes compared. <i>Translational Andrology and Urology</i> , 2020, 9, 1006-1008.	1.4	2
84	Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 381-387.	1.3	3
85	A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings. <i>BJU International</i> , 2020, 126, 104-113.	2.5	21
86	Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma. <i>Urology</i> , 2020, 140, 91-97.	1.0	2
87	Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 506-514.	1.6	4
88	Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>Journal of Endourology</i> , 2020, 34, 600-607.	2.1	6
89	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 459-464.	1.6	42
90	Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 MO nonurothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes. <i>International Journal of Urology</i> , 2020, 27, 402-407.	1.0	1

#	ARTICLE	IF	CITATIONS
91	Effects of MRI image normalization techniques in prostate cancer radiomics. <i>Physica Medica</i> , 2020, 71, 7-13.	0.7	52
92	Beyond PSA: The Role of Prostate Health Index (phi). <i>International Journal of Molecular Sciences</i> , 2020, 21, 1184.	4.1	45
93	Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. <i>Cancer Causes and Control</i> , 2020, 31, 263-272.	1.8	9
94	Insertion of a testicular prosthesis at the time of radical orchiectomy for testicular cancer is safe in patients who will subsequently undergo chemotherapy or radiotherapy. <i>Andrologia</i> , 2020, 52, e13613.	2.1	2
95	Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity score-matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. <i>BJU International</i> , 2020, 126, 114-123.	2.5	42
96	Robotic-assisted Laparoscopic Simple Enucleation in a Horseshoe Kidney. A Case Report and Review of the Literature. <i>Urology</i> , 2020, 143, 5-10.	1.0	4
97	Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder. <i>World Journal of Urology</i> , 2020, 38, 2819-2826.	2.2	10
98	Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. <i>Journal of Urology</i> , 2020, 203, 496-504.	0.4	61
99	Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: a double-blind placebo-controlled trial on prostate vascularity. <i>Aging</i> , 2020, 12, 4337-4347.	3.1	9
100	Systematic sampling during MRI-US fusion prostate biopsy can overcome errors of targeting—prospective single center experience after 300 cases in first biopsy setting. <i>Translational Andrology and Urology</i> , 2020, 9, 2510-2518.	1.4	5
101	Salvage high-dose-rate interstitial brachytherapy for perineal recurrence of prostate cancer after surgery and radiotherapy: a case report. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 492-496.	0.9	0
102	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 503-504.	0.4	1
103	Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 880-888.	1.3	5
104	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 507-514.	2.2	77
105	Sexual function recovery after robot-assisted radical prostatectomy: Outcomes from an Italian referral centre and predicting nomogram. <i>Andrologia</i> , 2019, 51, e13385.	2.1	8
106	Dysregulated metabolism: a relevant player in prostate cancer progression and clinical management. <i>Translational Andrology and Urology</i> , 2019, 8, S109-S111.	1.4	1
107	Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 578.e11-578.e19.	1.6	9
108	Radioablation +/and^~ hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159). <i>BMC Cancer</i> , 2019, 19, 903.	2.6	9

#	ARTICLE	IF	CITATIONS
109	Comparison of Outcomes and Toxicity Between Extreme and Moderate Radiation Therapy Hypofractionation in Localized Prostate Cancer: A Propensity Score Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 735-744.	0.8	6
110	Robot assisted radical prostatectomy in kidney transplant recipients: surgical, oncological and functional outcomes of two different robotic approaches. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 262-272.	1.5	19
111	Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e793-e801.	1.9	5
112	Predicting trajectories of recovery in prostate cancer patients undergone Robot-Assisted Radical Prostatectomy (RARP). <i>PLoS ONE</i> , 2019, 14, e0214682.	2.5	15
113	Low PI-RADS assessment category excludes extraprostatic extension (â‰¥pT3a) of prostate cancer: a histology-validated study including 301 operated patients. <i>European Radiology</i> , 2019, 29, 5478-5487.	4.5	20
114	Outcomes of Partial and Radical Nephrectomy in Octogenarians â€” A Multicenter International Study (Resurge). <i>Urology</i> , 2019, 129, 139-145.	1.0	9
115	Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 377-387.	3.1	43
116	Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients. <i>Cancer Epidemiology</i> , 2019, 59, 135-142.	1.9	9
117	Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation. <i>Radiologia Medica</i> , 2019, 124, 65-78.	7.7	17
118	Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). <i>British Journal of Radiology</i> , 2019, 92, 20180494.	2.2	50
119	Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. <i>World Journal of Urology</i> , 2019, 37, 1649-1657.	2.2	27
120	Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologistsâ€™ Training Program?. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 88-96.	1.9	22
121	â€œDeep-ontoâ€ network for surgical workflow and context recognition. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2019, 14, 685-696.	2.8	44
122	Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients. <i>Urologia Internationalis</i> , 2019, 102, 43-50.	1.3	43
123	Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials. <i>World Journal of Urology</i> , 2019, 37, 1049-1059.	2.2	5
124	Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 206-220.	3.9	19
125	Robot-assisted Partial Nephrectomy: 5-yr Oncological Outcomes at a Single European Tertiary Cancer Center. <i>European Urology Focus</i> , 2019, 5, 636-641.	3.1	19
126	Long-term oncologic and functional outcomes after robot-assisted partial nephrectomy in elderly patients. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 31-37.	3.9	26

#	ARTICLE	IF	CITATIONS
127	Bladder recurrence of primary upper tract urinary carcinoma following nephroureterectomy, and risk of upper urinary tract recurrence after ureteral stent positioning in patients with primary bladder cancer. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 191-200.	3.9	10
128	Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases. <i>Medical Oncology</i> , 2018, 35, 75.	2.5	19
129	Thulium Laser Treatment of Upper Urinary Tract Carcinoma: A Multi-Institutional Analysis of Surgical and Oncological Outcomes. <i>Journal of Endourology</i> , 2018, 32, 257-263.	2.1	51
130	Thulium-yttrium-aluminium-garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life. <i>World Journal of Urology</i> , 2018, 36, 265-270.	2.2	15
131	Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. <i>European Urology Oncology</i> , 2018, 1, 403-410.	5.4	66
132	Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. <i>Journal of Cancer</i> , 2018, 9, 4250-4254.	2.5	26
133	Patient Selection for Active Surveillance in the Multi-parametric Magnetic Resonance Imaging Era: A Step Forward in a Rapidly Evolving Field. <i>Annals of Surgical Oncology</i> , 2018, 25, 3423-3424.	1.5	1
134	Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). <i>European Urology</i> , 2018, 74, 226-232.	1.9	109
135	Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. <i>European Urology Oncology</i> , 2018, 1, 268-275.	5.4	5
136	High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. <i>Urologia Internationalis</i> , 2018, 101, 7-15.	1.3	22
137	A global Unified Dosimetry Index (gUDI) to evaluate simultaneous integrated boost radiotherapy plans in prostate cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 315-320.	0.6	6
138	Dual Combined Laparoscopic Approach for Renal-Cell Carcinoma with Renal Vein and Level II Inferior Vena Cava Thrombus: Our Technique and Initial Results. <i>Journal of Endourology</i> , 2018, 32, 837-842.	2.1	9
139	Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 445-452.	1.9	55
140	Give me five-ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach. <i>Medical Oncology</i> , 2018, 35, 96.	2.5	8
141	Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol. <i>Urologia Internationalis</i> , 2018, 101, 56-64.	1.3	17
142	Comparison Between 64Cu-PSMA-617 PET/CT and 18F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 385-391.	1.9	33
143	Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218. <i>British Journal of Radiology</i> , 2018, 91, 20160725.	2.2	9
144	Outcomes of robotic-assisted radical prostatectomy for patients in two extreme age-groups (< 50) Tj ETQq0 0 0 rgBT _{0,4} /Overlock 10 Tf 50		

#	ARTICLE	IF	CITATIONS
145	Splendiaphragmatic colonic interposition and left hemidiaphragmatic elevation in a patient undergoing robot-assisted radical prostatectomy: a case report. <i>Urology & Nephrology Open Access Journal</i> , 2018, 6, .	0.1	0
146	High-Risk Prostate Cancer and Radiotherapy: The Past and the Future. A Benchmark for a New Mixed Beam Radiotherapy Approach. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 376-383.	1.9	5
147	The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e661-e666.	1.9	47
148	Reliability of Frozen Section Examination in a Large Cohort of Testicular Masses: What Did We Learn?. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e689-e696.	1.9	39
149	Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e623-e632.	1.9	71
150	Cell-cycle Progression-score Might Improve the Current Risk Assessment in Newly Diagnosed Prostate Cancer Patients. <i>Urology</i> , 2017, 102, 73-78.	1.0	19
151	Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers. <i>Translational Research</i> , 2017, 184, 108-117.	5.0	56
152	Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA < 10 ng/ml. <i>Future Oncology</i> , 2017, 13, 1793-1800.	2.4	9
153	Outcomes of robot-assisted simple enucleation of renal masses. <i>Medicine (United States)</i> , 2017, 96, e6771.	1.0	4
154	Robot-Assisted Vesico-Vaginal Fistula Repair: Our Technique and Review of the Literature. <i>Urologia Internationalis</i> , 2017, 99, 137-142.	1.3	18
155	Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors. <i>Anti-Cancer Drugs</i> , 2017, 28, 206-212.	1.4	9
156	Virtue male sling for post-prostatectomy stress incontinence: a prospective evaluation and mid-term outcomes. <i>BJU International</i> , 2017, 119, 482-488.	2.5	34
157	The emerging role of obesity, diet and lipid metabolism in prostate cancer. <i>Future Oncology</i> , 2017, 13, 285-293.	2.4	55
158	Meta-analysis of studies comparing oncologic outcomes of radical prostatectomy and brachytherapy for localized prostate cancer. <i>Therapeutic Advances in Urology</i> , 2017, 9, 241-250.	2.0	7
159	Phase II Multi-institutional Clinical Trial on a New Mixed Beam RT Scheme of IMRT on Pelvis Combined with a Carbon Ion Boost for High-risk Prostate Cancer Patients. <i>Tumori</i> , 2017, 103, 314-318.	1.1	12
160	Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome. <i>Ecancermedalscience</i> , 2017, 11, 786.	1.1	5
161	Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. <i>Oncotarget</i> , 2017, 8, 18424-18434.	1.8	52
162	Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience. <i>Ecancermedalscience</i> , 2016, 10, 657.	1.1	4

#	ARTICLE	IF	CITATIONS
163	Rationale and Protocol of AIRC IG-13218, Short-Term Radiotherapy for Early Prostate Cancer with Concomitant Boost to the Dominant Lesion. <i>Tumori</i> , 2016, 102, 536-540.	1.1	15
164	External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non-muscle invasive bladder cancer stages Ta and T1. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2016, 42, 932-941.	1.5	6
165	No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy. <i>British Journal of Radiology</i> , 2016, 89, 20150985.	2.2	7
166	Trends in the use of partial nephrectomy for cT1 renal tumors: Analysis of a 10-yr European multicenter dataset. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1729-1735.	1.0	35
167	Role of Multi-Parametric Magnetic Resonance Image and PIRADS Score in Patients with Prostate Cancer Eligible for Active Surveillance According PRIAS Criteria. <i>Urologia Internationalis</i> , 2016, 96, 459-469.	1.3	27
168	Impact of novel techniques on minimally invasive adrenal surgery: trends and outcomes from a contemporary international large series in urology. <i>World Journal of Urology</i> , 2016, 34, 1473-1479.	2.2	19
169	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1387-1401.	3.1	22
170	Primary focal prostate radiotherapy: Do all patients really need whole-prostate irradiation?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 100-111.	4.4	6
171	Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy. <i>Medicine (United States)</i> , 2016, 95, e4519.	1.0	20
172	Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-GuÃ©rin for Adjuvant Treatment of Patients with Intermediate- and High-risk Nonâ€Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2016, 69, 1046-1052.	1.9	176
173	Biomarkers in localized prostate cancer. <i>Future Oncology</i> , 2016, 12, 399-411.	2.4	39
174	Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 324-331.	4.4	11
175	Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database. <i>European Journal of Surgical Oncology</i> , 2016, 42, 744-750.	1.0	51
176	EORTC Risk Model to Predict Progression in Patients With Nonâ€Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 176-182.	1.9	24
177	PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. <i>World Journal of Urology</i> , 2016, 34, 485-493.	2.2	41
178	Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis. <i>Oncotarget</i> , 2016, 7, 20636-20654.	1.8	66
179	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. <i>Medicine (United States)</i> , 2015, 94, e1861.	1.0	43
180	Third-Line Chemotherapy for Metastatic Urothelial Cancer. <i>Medicine (United States)</i> , 2015, 94, e2297.	1.0	16

#	ARTICLE	IF	CITATIONS
181	Urinary Bladder Preservation for Muscle-invasive Bladder Cancer: A Survey among Radiation Oncologists of Lombardy, Italy. <i>Tumori</i> , 2015, 101, 174-178.	1.1	9
182	Hyperhomocysteinemia as an Early Predictor of Erectile Dysfunction. <i>Medicine (United States)</i> , 2015, 94, e1556.	1.0	34
183	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e2117.	1.0	45
184	The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo. <i>International Journal of Oncology</i> , 2015, 47, 527-534.	3.3	71
185	Robot-assisted Radical Prostatectomy: Multiparametric MR Imaging-directed Intraoperative Frozen-Section Analysis to Reduce the Rate of Positive Surgical Margins. <i>Radiology</i> , 2015, 274, 434-444.	7.3	48
186	Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 163.e15-163.e23.	1.6	40
187	Salvage image-guided intensity modulated or stereotactic body reirradiation of local recurrence of prostate cancer. <i>British Journal of Radiology</i> , 2015, 88, 20150197.	2.2	38
188	Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis. <i>European Urology</i> , 2015, 68, 86-94.	1.9	145
189	The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 1970-1977.	2.8	31
190	Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 201.e1-201.e8.	1.6	54
191	Evaluation of the Prognostic Significance of Perirenal Fat Invasion and Tumor Size in Patients with pT1-pT3a Localized Renal Cell Carcinoma in a Comprehensive Multicenter Study of the CORONA project. Can We Improve Prognostic Discrimination for Patients with Stage pT3a tumors?. <i>European Urology</i> , 2015, 67, 943-951.	1.9	45
192	Salvage Radical Prostatectomy after External Beam Radiation Therapy: A Systematic Review of Current Approaches. <i>Urologia Internationalis</i> , 2015, 94, 373-382.	1.3	38
193	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015, 11, 3091-3098.	2.4	17
194	Radiotherapy in Prostate Cancer Patients With Pelvic Lymphocele After Surgery: Clinical and Dosimetric Data of 30 Patients. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e223-e228.	1.9	6
195	Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging. <i>PLoS ONE</i> , 2015, 10, e0139696.	2.5	39
196	Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. <i>Anticancer Research</i> , 2015, 35, 1017-23.	1.1	35
197	Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2014, 10, 1353-1360.	2.4	23
198	Reporting combined outcomes with Trifecta and survival, continence, and potency (SCP) classification in 337 patients with prostate cancer treated with image-guided hypofractionated radiotherapy. <i>BJU International</i> , 2014, 114, E3-E10.	2.5	7

#	ARTICLE	IF	CITATIONS
199	Linac-based Stereotactic Body Radiotherapy for Oligometastatic Patients With Single Abdominal Lymph Node Recurrent Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 227-233.	1.3	71
200	[11C]Choline PET/CT Impacts Treatment Decision Making in Patients With Prostate Cancer Referred for Radiotherapy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 155-159.	1.9	20
201	Prostate positioning using cone-beam computer tomography based on manual soft-tissue registration. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 81-87.	2.0	13
202	Do Young Patients with Renal Cell Carcinoma Feature a Distinct Outcome after Surgery? A Comparative Analysis of Patient Age Based on the Multinational CORONA Database. <i>Journal of Urology</i> , 2014, 191, 310-315.	0.4	20
203	Results of a comparative study analyzing octogenarians with renal cell carcinoma in a competing risk analysis with patients in the seventh decade of life1Matthias May and Luca Cindolo have equally contributed to first authorship.2Sabine Brookman-May and Petros Sountoulides have equally contributed to last authorship.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1252-1258.	1.6	8
204	Chronic bacterial prostatitis: efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®). <i>BMC Urology</i> , 2014, 14, 53.	1.4	37
205	Reparación totalmente laparoscópica de megauréter obstructivo primario con pieloplastia, preparación escisional completa y reimplante ureteral sin reflujo. <i>Actas Urológicas Españolas</i> , 2014, 38, 127-132.	0.7	0
206	Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. <i>World Journal of Urology</i> , 2013, 31, 1073-1080.	2.2	39
207	The use of mannitol in partial and live donor nephrectomy: an international survey. <i>World Journal of Urology</i> , 2013, 31, 977-982.	2.2	42
208	A novel "intuitive" surgical technique for right robot-assisted retroperitoneal lymph node dissection for stage I testicular NSGCT. <i>World Journal of Urology</i> , 2013, 31, 435-439.	2.2	10
209	Long-Term Follow-Up Using Testicle-Sparing Surgery for Leydig Cell Tumor. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 321-324.	1.9	45
210	Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project). <i>European Urology</i> , 2013, 64, 472-477.	1.9	91
211	Intraoperative Frozen Pathology During Robot-Assisted Laparoscopic Radical Prostatectomy: Can ALEXIS, Trocar Make it Easy and Fast?. <i>Journal of Endourology</i> , 2013, 27, 1213-1217.	2.1	10
212	1076 INDEPENDENT VALIDATION OF THE 2010 TNM STAGING SYSTEM FOR RENAL CELL CARCINOMA: DOES IT IMPROVE PREDICTIVE ACCURACY IN CANCER-SPECIFIC MORTALITY COMPARED TO 2002 TNM?. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
213	Image Guided Hypofractionated Radiotherapy and Quality of Life for Localized Prostate Cancer: Prospective Longitudinal Study in 337 Patients. <i>Journal of Urology</i> , 2013, 189, 2099-2103.	0.4	19
214	Prognostic Effect of Sarcomatoid Dedifferentiation in Patients With Surgically Treated Renal Cell Carcinoma: A Matched-Pair Analysis. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 465-470.	1.9	10
215	A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 557-565.	1.6	4
216	Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma " results from a comprehensive multicentre database (<sc>CORONA</sc></sc>SATURN</sc></sc> project). <i>BJU International</i> , 2013, 112, 909-916.	2.5	69

#	ARTICLE	IF	CITATIONS
217	Assessing the accuracy and generalizability of the preoperative and postoperative arakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study. <i>BJU International</i> , 2013, 112, 578-584.	2.5	18
218	Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2-10 ng/ml. <i>PLoS ONE</i> , 2013, 8, e67687.	2.5	87
219	ecancermedalscience. <i>Ecancermedalscience</i> , 2012, 6, 252.	1.1	4
220	Adherence to Guidelines among Italian Urologists on Imaging Preoperative Staging of Low-Risk Prostate Cancer: Results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy) Trial. <i>Urology</i> , 2013, 81, 100-105.	1.0	10
221	Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer: A Systematic Diagnostic Attempt. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 164-173.	1.9	45
222	Robotic Image-Guided Stereotactic Radiotherapy, for Isolated Recurrent Primary, Lymph Node or Metastatic Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 889-897.	0.8	221
223	922 LONG-TERM FOLLOW UP USING TESTICULAR SPARING SURGERY FOR LEYDIG CELL TUMOR. <i>Journal of Urology</i> , 2012, 187, .	0.4	0
224	Robot-assisted simple prostatectomy (RASP): does it make sense?. <i>BJU International</i> , 2012, 110, E972-9.	2.5	88
225	Multidisciplinary approach in the treatment of patients with small cell bladder carcinoma. <i>European Journal of Surgical Oncology</i> , 2011, 37, 558-562.	1.0	20
226	Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: Nonrandomized comparison with conventional fractionation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 523-532.	1.6	28
227	Collecting System Invasion and Fuhrman Grade But Not Tumor Size Facilitate Prognostic Stratification of Patients With pT2 Renal Cell Carcinoma. <i>Journal of Urology</i> , 2011, 186, 2175-2181.	0.4	16
228	Factors predicting continence recovery 1-month after radical prostatectomy: Results of a multicenter survey. <i>International Journal of Urology</i> , 2011, 18, 700-708.	1.0	38
229	Patients' Desire to Preserve Sexual Activity and Final Decision for a Nerve-Sparing Approach: Results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study. <i>Journal of Sexual Medicine</i> , 2011, 8, 1495-1502.	0.6	13
230	An Open, Randomised, Multicentre, Phase 3 Trial Comparing the Efficacy of Two Tamoxifen Schedules in Preventing Gynaecomastia Induced by Bicalutamide Monotherapy in Prostate Cancer Patients. <i>European Urology</i> , 2010, 57, 238-245.	1.9	35
231	Validation of the 2009 TNM Version in a Large Multi-Institutional Cohort of Patients Treated for Renal Cell Carcinoma: Are Further Improvements Needed?. <i>European Urology</i> , 2010, 58, 588-595.	1.9	205
232	Correlation Between Acute and Late Toxicity in 973 Prostate Cancer Patients Treated With Three-Dimensional Conformal External Beam Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 26-34.	0.8	48
233	Health-Related Quality of Life in Patients with Hormone Refractory Prostate Cancer Receiving Gefitinib. <i>Urologia Internationalis</i> , 2009, 82, 196-202.	1.3	5
234	Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. <i>Annals of Oncology</i> , 2009, 20, 498-502.	1.2	9

#	ARTICLE	IF	CITATIONS
235	Cisplatin, Etoposide and Continuous Infusion Bleomycin in Patients with Testicular Germ Cell Tumors: Efficacy and Toxicity Data from a Retrospective Study. <i>Journal of Chemotherapy</i> , 2009, 21, 687-692.	1.5	7
236	Robotic vs open prostatectomy in a laparoscopically naive centre: a matchedâ€pair analysis. <i>BJU International</i> , 2009, 104, 991-995.	2.5	152
237	Intraoperative radiotherapy during radical prostatectomy for intermediateâ€risk to locally advanced prostate cancer: treatment technique and evaluation of perioperative and functional outcome vs standard radical prostatectomy, in a matchedâ€pair analysis. <i>BJU International</i> , 2009, 104, 1624-1630.	2.5	16
238	Sooner or Later? Outcome Analysis of 431 Prostate Cancer Patients Treated With Postoperative or Salvage Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 115-125.	0.8	42
239	Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. <i>Radiotherapy and Oncology</i> , 2009, 93, 14-17.	0.6	72
240	Local staging of penile cancer using magnetic resonance imaging with pharmacologically induced penile erection. <i>Radiologia Medica</i> , 2008, 113, 517-528.	7.7	54
241	Dose Escalation for Prostate Cancer Using the Three-Dimensional Conformal Dynamic Arc Technique: Analysis of 542 Consecutive Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 784-794.	0.8	31
242	INTRAOPERATIVE RADIOTHERAPY FOR LOCALLY ADVANCED PROSTATE CANCER: THE EXPERIENCE OF THE EUROPEAN INSTITUTE OF ONCOLOGY. <i>Journal of Urology</i> , 2008, 179, 183-183.	0.4	0
243	Circulating Levels of VCAM and MMP-2 May Help Identify Patients with More Aggressive Prostate Cancer. <i>Current Cancer Drug Targets</i> , 2008, 8, 199-206.	1.6	23
244	Benefit on Biochemical Control of Adjuvant Radiation Therapy in Patients with Pathologically Involved Seminal Vesicles after Radical Prostatectomy. <i>Tumori</i> , 2007, 93, 445-451.	1.1	4
245	Locally advanced prostate cancer: Biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. <i>Cancer</i> , 2007, 110, 467-468.	4.1	15
246	Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. <i>Prostate</i> , 2007, 67, 603-604.	2.3	17
247	Is the era of prostate-specific antigen over?. <i>BJU International</i> , 2007, 100, 8-10.	2.5	4
248	European Study of Radical Prostatectomy: time trends in Europe, 1993?2005. <i>BJU International</i> , 2007, 100, 22-25.	2.5	13
249	Transabdominal Ultrasonography, Computed Tomography and Electronic Portal Imaging for 3-Dimensional Conformal Radiotherapy for Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 610-616.	2.0	30
250	Treatment of Ureterointestinal Anastomotic Strictures by Diathermal or Cryoplastic Dilatation. <i>CardioVascular and Interventional Radiology</i> , 2007, 30, 943-949.	2.0	14
251	Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. <i>Anti-Cancer Drugs</i> , 2007, 18, 949-954.	1.4	12
252	242: Pharmacogenetics Determinants of Anticancer Activity of Intravesical Gemcitabine in Patients with Superficial Transitional Cell Carcinoma (TCC) of The Bladder. <i>Journal of Urology</i> , 2007, 177, 81-81.	0.4	0

#	ARTICLE	IF	CITATIONS
253	Intraoperative radiotherapy for locally advanced prostate cancer: treatment technique and ultrasound-based analysis of dose distribution. <i>Anticancer Research</i> , 2007, 27, 3471-6.	1.1	13
254	Dose distribution in 3-dimensional conformal radiotherapy for prostate cancer: Comparison of two treatment techniques (six coplanar fields and two dynamic arcs). <i>Radiotherapy and Oncology</i> , 2006, 81, 294-302.	0.6	17
255	In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. <i>British Journal of Cancer</i> , 2006, 95, 289-297.	6.4	43
256	Sensitivity and Detection Rate of a 12-Core Trans-Perineal Prostate Biopsy: Preliminary Report. <i>European Urology</i> , 2006, 49, 827-833.	1.9	35
257	“Burned out” phenomenon of the testis in retroperitoneal seminoma. <i>Acta Oncologica</i> , 2006, 45, 335-336.	1.8	15
258	Cancer of the prostate. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 379-396.	4.4	89
259	Synchronous collecting duct carcinoma and papillary renal cell carcinoma: a case report and review of the literature. <i>Anticancer Research</i> , 2005, 25, 579-86.	1.1	18
260	Androgen Ablation Therapy Does not Increase the Risk of Late Morbidity following 3D-conformal Radiotherapy of Organ-confined Prostate Cancer: The Experience of the European Institute of Oncology. <i>Tumori</i> , 2004, 90, 567-572.	1.1	3
261	Prostate Cancer with Low PSA Levels. <i>New England Journal of Medicine</i> , 2004, 351, 1802-1803.	27.0	4
262	Letter to the Editor Re: Wirth MP, Weissbach L, Marx F-J, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. <i>Eur Urol</i> 2004;45:267-70. <i>European Urology</i> , 2004, 46, 272-273.	1.9	7
263	MR and CT image fusion for postimplant analysis in permanent prostate seed implants. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1572-1579.	0.8	90
264	RE: AN EVALUATION OF THE DECREASING INCIDENCE OF POSITIVE SURGICAL MARGINS IN A LARGE RETROPUBIC PROSTATECTOMY SERIES. <i>Journal of Urology</i> , 2004, 172, 776-776.	0.4	2
265	Magnetic resonance imaging combined with artificial erection for local staging of penile cancer. <i>Urology</i> , 2004, 63, 1158-1162.	1.0	72
266	Basaloid cell carcinoma of the prostate. Case report and review of the literature. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 443, 787-791.	2.8	29
267	Localization of Avidin in Superficial Bladder Cancer: A Potentially New Approach for Radionuclide Therapy. <i>European Urology</i> , 2003, 44, 556-559.	1.9	19
268	Re: Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. <i>Journal of Urology</i> , 2002, 168, 662-3; author reply 663.	0.4	1
269	Impact of the COVID-19 pandemic on urological cancers: The surgical experience of two cancer hubs in London and Milan. <i>BJUI Compass</i> , 0, , .	1.3	3